Hoskin Justin L, Fife Terry D
Department of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine, Phoenix, AZ, United States.
Front Neurol. 2022 Jan 27;12:799002. doi: 10.3389/fneur.2021.799002. eCollection 2021.
Vestibular migraine (VM) is a condition associated with migraine headache, vertigo, dizziness, and balance disturbances. Treatment options are limited. It is unknown if new calcitonin gene-related peptide (CGRP) migraine medications have efficacy in treating VM.
We retrospectively reviewed all patients with VM who were prescribed one of the new CGRP medications between January 2016 and July 2020. In total, 28 patients met the inclusion criteria. We specifically evaluated the "older" CGRP medications including erenumab, galcanezumab, fremanezumab, and ubrogepant. Medical records for subsequent visits were assessed to monitor improvement described by patients.
Of the 28 patients identified, three were lost to follow up. For the remaining 25 patients, we divided the patients based on a scale of "significant improvement," "moderate improvement," "mild improvement," or "no improvement." In total 21 of 25 patients demonstrated some level of improvement in their VM symptoms with 15 having moderate to significant improvement.
Results demonstrated a trend toward improvement, suggesting that the CGRP medications appear to be a decent treatment option for VM. A prospective study evaluating CGRP medications in patients with VM would provide further information about this treatment option.
前庭性偏头痛（VM）是一种与偏头痛性头痛、眩晕、头晕和平衡障碍相关的疾病。治疗选择有限。新型降钙素基因相关肽（CGRP）偏头痛药物对VM是否有效尚不清楚。
我们回顾性分析了2016年1月至2020年7月期间所有开具新型CGRP药物之一的VM患者。共有28例患者符合纳入标准。我们专门评估了“较老的”CGRP药物，包括erenumab、galcanezumab、fremanezumab和ubrogepant。对后续就诊的病历进行评估，以监测患者描述的改善情况。
在确定的28例患者中，3例失访。对于其余25例患者，我们根据“显著改善”“中度改善”“轻度改善”或“无改善”的量表对患者进行划分。25例患者中有21例的VM症状有一定程度的改善，其中15例有中度至显著改善。
结果显示出改善的趋势，表明CGRP药物似乎是VM的一种不错的治疗选择。一项评估CGRP药物对VM患者疗效的前瞻性研究将提供有关这种治疗选择的更多信息。
